How GLP-1 Is Reshaping Europe’s Consumer Basket

• 11% of U.S. adults now use GLP-1 drugs for weight loss, while European adoption remains far lower

• American users are buying smaller portions and more protein, while snacks, alcohol, impulse purchases, and conventional meal sizes lose ground

• Europe’s opportunity is to redesign value around nutrition, packaging, households, and the money that moves beyond food

Eleven percent of American adults now use GLP-1 medicines specifically for weight loss. Gallup’s September 8, 2026 update, based on a probability sample of 5,065 adults, puts the figure at nearly four times its 2024 level. Europe is much earlier. ING Research estimated in March 2026 that at least 2% of adults across Europe and the United Kingdom were current users, roughly nine to ten million people. No equally fresh pan-European prevalence estimate was available in September, but the gap is real and large.

America Is Further Ahead

The potential user base is substantial on both sides of the Atlantic. The U.S. National Center for Health Statistics reported in February 2026 that 72.4% of adults aged 20 and over were overweight or obese, including 40.3% with obesity. Eurostat reported on September 4 that 51.7% of EU adults were overweight in 2025, including 16.3% with obesity. The methods differ, because U.S. figures are measured while European figures rely heavily on self-reporting, but both markets contain large populations for whom weight management matters.

Europe also has room for adoption. PwC Ireland reported on September 4 that 6% of Irish adults currently use GLP-1 prescription medicines and another 21% would consider using them. Reuters reported on September 1 that Germany had become the first EU market to launch the oral Wegovy pill. PwC UK estimated in June that pill-based treatment could lift current UK use from roughly three million adults to seven million. Europe will move unevenly, but access is widening.

The Basket Has Changed

America is already showing what that can mean in a supermarket. Research released by the National Frozen & Refrigerated Foods Association on September 1, based on a Morning Consult survey of 2,003 U.S. adults including 241 current GLP-1 users, found that 52% were buying more high-protein dairy and 48% more single-serve or portion-controlled foods. Forty-three percent were buying more protein drinks. These are foods that make a smaller eating occasion work harder.

The same survey found that 44% of users were spending more per grocery trip and 41% more overall, even as impulse purchases declined. That complicates the assumption that smaller appetite means lower value. A smaller product can command value when it delivers enough protein, fibre, convenience and satisfaction. Cheap excess becomes less attractive when nobody wants to finish it.

Impulse Is the Question

A randomized controlled trial published in the August 2026 issue of The American Journal of Clinical Nutrition found that participants taking semaglutide consumed roughly 240 to 292 fewer calories than the placebo group during laboratory meals at weeks 20, 40 and 60. Responsiveness to the rewarding value of food was also lower at weeks 20 and 40.

No study has yet shown that a checkout chocolate bar or a snack promotion becomes less effective by a specific percentage among GLP-1 users. But retailers now have a reason to measure it. If appetite suppression reduces response to food cues, promotion lift and unplanned basket additions may weaken before total store revenue does. Loyalty-card data could reveal that shift early.

Europe Is Testing Formats

IGD reported in January 2026 that M&S, Co-op and Morrisons were introducing private-label ranges built around smaller portions, protein, fibre and nutrient density. Morrisons’ Small and Balanced meals were about 30% smaller than standard ready meals while remaining broadly at price parity. That detail matters. Less food at almost the same price can look like shrinkflation; a smaller meal designed around a reduced appetite has to earn its price through usefulness.

Packaging may become part of that usefulness. In the September NFRA research, 42% of current U.S. users said frozen and refrigerated foods helped them control portions, while 37% said they helped avoid wasting fresh food. That points toward resealable formats, protected portions and family packs that no longer assume everyone at the table wants the same amount.

One Prescription Travels

BCG reported in August 2026 that 70% of GLP-1 users surveyed saw changes in food or fitness behaviour among people they lived with. Non-users adopted an estimated 30% to 50% of the user’s behavioural changes. BCG calculates that household spillovers make the addressable market for GLP-1-influenced demand roughly 50% larger than the active-user population alone.

The cultural effect is less settled. A June 2026 paper in Body Image concluded that GLP-1 medicines may influence social norms around weight and appearance, while stressing that the evidence remains limited. There is not yet support for saying they have caused a universal return to thinness. There is stronger evidence that active weight management is becoming more visible. PwC Ireland found in September that 40% of consumers named losing weight as a health goal, while 81% used health apps or wearables.

The Wallet Keeps Moving

PwC reported in June 2026 that 21% of U.S. households contained at least one current GLP-1 user. Grocery spending per household was down 5.5%, while apparel spending rose 9.9% after six to eight months, and 73% of users reported a meaningful change in clothing size. BCG also found expected increases in supplements, fitness, clothing, footwear and self-care.

McKinsey estimated in April 2026 that GLP-1 adoption would reduce European grocery revenue by less than 1%. That sounds small until set against its forecast of only about 0.2% annual grocery volume growth through 2030. Europe does not need to reach American adoption levels before the change becomes visible.

The first signals may be smaller portions, weaker impulse purchases, different packaging and money moving elsewhere.

For an industry trained to create growth by selling more volume, the harder question is arriving first: what is a product worth when the customer genuinely wants less of it?